Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Mizuho Maintains Buy on Leap Therapeutics, Lowers Price Target to $12

Author: Benzinga Newsdesk | November 20, 2023 11:40am
Mizuho analyst Mara Goldstein maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $20 to $12.

Posted In: LPTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist